Muscular Dystrophy UK is delighted to announce the launch of its 2021 grant round.
Researchers are invited to submit their ideas for exciting research projects in areas of muscle-wasting and associated conditions.
The 2021 grant round looks a little different to previous years because of the impact of the ongoing Covid-19 pandemic.
We are looking to fund research projects of up to one year in six specific conditions. These are:
- Becker muscular dystrophy
- Collagen VI related neuromuscular conditions
- Duchenne muscular dystrophy
- Facioscapulohumeral muscular dystrophy
- Myotonic dystrophy
- Congenital myotonic dystrophy
In addition, MDUK is excited to announce a partnership with SMA UK as part of the 2021 grant round. MDUK and SMA UK hope to support one 4-year PhD studentship in SMA research.
Each research application for the grants will undergo a rigorous review process to ensure that we are funding top-quality science that is both meaningful and relevant for people with muscle-wasting conditions.
MDUK expects to release details on successful applications at the start of 2022.
2021 marks a welcome return for the grant round, which was cancelled last year in light of the financial impact that Covid-19 had on the charity. This difficult decision was taken to allow us to protect as many of our existing research projects as possible.
MDUK continues to support almost 40 research grants into 16 different muscle-wasting conditions. We could not do this without the on-going support of our community.
In 2022 we hope to include all muscle-wasting conditions in our call for proposals.
Dr Kate Adcock, Director of Research and Innovation at MDUK, said:
“Thanks to the generous support of our community we are able to build on our portfolio of research activities and invest in new high-quality research through our grant round. This will build on our understanding of the underlying causes of conditions, enable the development of potential treatments and improve the quality of life for people living with neuromuscular conditions.”